Edition:
United Kingdom

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

12,950.00ZAc
14 Dec 2018
Change (% chg)

-1,214.00 (-8.57%)
Prev Close
14,164.00
Open
13,350.00
Day's High
13,495.00
Day's Low
12,818.00
Volume
6,452,500
Avg. Vol
2,166,836
52-wk High
29,800.00
52-wk Low
12,818.00

Select another date:

Fri, Dec 14 2018

UPDATE 1-Aspen Pharmacare drops on debt worries and revenue forecast

JOHANNESBURG, Dec 14 Shares in Aspen Pharmacare fell more than 8 percent on Friday, a day after the South African drugmaker said it had negotiated a temporary relaxation of its lending agreements and forecast little growth in full-year revenues.

South Africa's Aspen strikes distribution deal with U.S. drugmaker Mylan

JOHANNESBURG Aspen Pharmacare has struck a deal with U.S. generics maker Mylan to distribute a portfolio of prescription and over-the-counter drugs in Australia and New Zealand.

UPDATE 1-South Africa's Aspen strikes distribution deal with U.S. drugmaker Mylan

JOHANNESBURG, Dec 13 Aspen Pharmacare has struck a deal with U.S. generics maker Mylan to distribute a portfolio of prescription and over-the-counter drugs in Australia and New Zealand.

South Africa's Aspen launches three-in-one HIV drug

JOHANNESBURG South African drugmaker Aspen Pharmacare on Monday launched a triple-combination tablet for the treatment of HIV in the country where the virus is most prevalent.

South Africa's Aspen launches three-in-one HIV drug

JOHANNESBURG, Nov 26 South African drugmaker Aspen Pharmacare on Monday launched a triple-combination tablet for the treatment of HIV in the country where the virus is most prevalent.

South Africa’s Aspen to invest $231 million in sterile anaesthetics manufacturing

JOHANNESBURG, Oct 26 South African drug maker Aspen Pharmacare will invest an additional 3.4 billion rand ($231 million) at its Port Elizabeth plant, it said on Friday at an investment summit in Johannesburg.

Aspen Pharma suffers week of woe as valuation tumbles by $3 bln

* Investors spooked by debt levels and sale of baby milk business

Drugmaker Aspen sells baby milk business to dairy giant Lactalis

JOHANNESBURG Aspen Pharmacare has agreed to sell its infant formula business to Lactalis for 12.9 billion rand (660.64 million pounds) to focus on core activities while the French buyer looks to revive its baby milk expansion after a health scandal.

South Africa's Aspen sells infant formula business to Lactalis for $865 million

JOHANNESBURG African drugmaker Aspen Pharmacare has agreed to sell its infant formula business to French dairy group Lactalis for 12.9 billion rand ($865 million), looking to capitalise on the sector's recent flurry of dealmaking to reduce its debt and focus on core operations.

Lactalis says Aspen deal to boost overseas business

PARIS Privately held French dairy group Lactalis said on Thursday its takeover of Aspen's global infant formula business would boost its presence in Latin America, Africa, Australia and Asia.

Select another date: